Literature DB >> 25315390

Early phytocannabinoid chemistry to endocannabinoids and beyond.

Raphael Mechoulam1, Lumír O Hanuš1, Roger Pertwee2, Allyn C Howlett3.   

Abstract

Isolation and structure elucidation of most of the major cannabinoid constituents--including Δ(9)-tetrahydrocannabinol (Δ(9)-THC), which is the principal psychoactive molecule in Cannabis sativa--was achieved in the 1960s and 1970s. It was followed by the identification of two cannabinoid receptors in the 1980s and the early 1990s and by the identification of the endocannabinoids shortly thereafter. There have since been considerable advances in our understanding of the endocannabinoid system and its function in the brain, which reveal potential therapeutic targets for a wide range of brain disorders.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25315390     DOI: 10.1038/nrn3811

Source DB:  PubMed          Journal:  Nat Rev Neurosci        ISSN: 1471-003X            Impact factor:   34.870


  96 in total

Review 1.  Endocannabinoid signalling in reward and addiction.

Authors:  Loren H Parsons; Yasmin L Hurd
Journal:  Nat Rev Neurosci       Date:  2015-09-16       Impact factor: 34.870

Review 2.  Complementary and Alternative Therapies in Amyotrophic Lateral Sclerosis.

Authors:  Richard S Bedlack; Nanette Joyce; Gregory T Carter; Sabrina Paganoni; Chafic Karam
Journal:  Neurol Clin       Date:  2015-09-08       Impact factor: 3.806

3.  HU-444, a Novel, Potent Anti-Inflammatory, Nonpsychotropic Cannabinoid.

Authors:  Christeene G Haj; Percy F Sumariwalla; Lumír Hanuš; Natalya M Kogan; Zhana Yektin; Raphael Mechoulam; Mark Feldmann; Ruth Gallily
Journal:  J Pharmacol Exp Ther       Date:  2015-08-13       Impact factor: 4.030

Review 4.  Cannabis and the Developing Brain: Insights into Its Long-Lasting Effects.

Authors:  Yasmin L Hurd; Olivier J Manzoni; Mikhail V Pletnikov; Francis S Lee; Sagnik Bhattacharyya; Miriam Melis
Journal:  J Neurosci       Date:  2019-10-16       Impact factor: 6.167

Review 5.  Reward, Control & Decision-Making in Cannabis Use Disorder: Insights from Functional MRI.

Authors:  Hudaisa Fatima; Allyn C Howlett; Christopher T Whitlow
Journal:  Br J Radiol       Date:  2019-08-09       Impact factor: 3.039

6.  Cannabis for rheumatic pain: hope or hype?

Authors:  Glen S Hazlewood; Omid Zahedi Niaki; Mary-Ann Fitzcharles
Journal:  Clin Rheumatol       Date:  2019-07-05       Impact factor: 2.980

7.  Cannabis: A potential efficacious intervention for PTSD or simply snake oil?

Authors:  Alfonso Abizaid; Zul Merali; Hymie Anisman
Journal:  J Psychiatry Neurosci       Date:  2019-03-01       Impact factor: 6.186

8.  Critical period plasticity-related transcriptional aberrations in schizophrenia and bipolar disorder.

Authors:  Milo R Smith; Ben Readhead; Joel T Dudley; Hirofumi Morishita
Journal:  Schizophr Res       Date:  2018-11-12       Impact factor: 4.939

9.  Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis.

Authors:  María Gómez-Cañas; Gemma Navarro; Paula Morales; Dow P Hurst; Francisco J Carrillo-Salinas; Laura Lagartera; Ruth Pazos; Pilar Goya; Patricia H Reggio; Carmen Guaza; Rafael Franco; Javier Fernández-Ruiz; Nadine Jagerovic
Journal:  J Med Chem       Date:  2016-07-06       Impact factor: 7.446

Review 10.  Medical Cannabis for Older Patients.

Authors:  Amir Minerbi; Winfried Häuser; Mary-Ann Fitzcharles
Journal:  Drugs Aging       Date:  2019-01       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.